By Cyber Sense Billing Team · Published · Updated
Why drug payment rules shape oncology finances
For community oncology practices, drugs administered in the office often represent most of the practice's revenue and expense. A single claim can include thousands of dollars in drug cost. Payment methods differ between Medicare and commercial plans, and even among commercial plans. Some pay a percentage of a published price, some pay fixed fee schedules, and some require that drugs be obtained through specialty pharmacies rather than bought by the practice. Understanding these differences helps practices check payments, negotiate contracts, and decide when buying and billing a drug is financially sustainable.
Medicare Part B and average sales price
Medicare Part B pays for most physician-administered drugs based on the average sales price methodology, with payment limits published quarterly by CMS in the ASP pricing files. The statutory payment is generally ASP plus a percentage add-on, subject to sequestration reductions. Because ASP updates every quarter, the expected payment for a drug can change several times a year. Practices should load the current quarterly file into their billing system so expected payments are accurate, and compare their acquisition cost against the payment limit to identify drugs that are paid below cost.
Commercial contracts and pricing benchmarks
Commercial plans set drug payment in their contracts. Common benchmarks include a percentage of ASP, a percentage of wholesale acquisition cost, average wholesale price less a discount, or a fixed fee schedule. Contracts may lag behind quarterly price changes, and new drugs may not be on the plan's fee schedule when they first launch. When a new drug is not priced, plans may pay a percentage of billed charges or request an invoice. Track these situations closely so new therapies do not create unexpected losses.
NDC reporting and units
Most payers require the National Drug Code, the quantity in the NDC unit of measure, and the HCPCS code with billing units. Errors between the NDC quantity and HCPCS units are a frequent cause of denials. Medicaid programs require NDCs for drug rebate purposes, and many commercial plans also require them. Medicare requires JW or JZ modifiers to report discarded drug amounts or confirm no waste for single-dose containers. Commercial plans may or may not follow those modifier rules.
Site-of-care and specialty pharmacy policies
Many commercial plans have site-of-care policies that require certain infusions to be given in the lowest-cost appropriate setting, such as a physician office or home infusion, rather than a hospital outpatient department. Some plans also require white bagging, where a specialty pharmacy ships the drug for a specific patient to the practice, or brown bagging, where the patient brings it. In those cases, the practice bills only administration, not the drug. These arrangements affect inventory, scheduling, and liability, and should be noted in the patient's authorization record.
Medicare Advantage differences
Medicare Advantage plans often pay drugs based on Medicare ASP methodology but apply their own prior authorization, step therapy, and site-of-care rules. Some plans have introduced step therapy for Part B drugs, such as requiring a biosimilar before a reference biologic. Do not assume a Medicare Advantage patient follows traditional Medicare rules; verify each plan's drug policies during authorization.
Monitoring payments and underpayments
Practices should compare every drug payment to the expected amount for that payer and date of service. Underpayments can come from outdated fee schedules, incorrect units, missing NDCs, or contract errors. A monthly report of drug payments below expected, grouped by drug and payer, shows where to dispute claims and where contracts need renegotiation. Accurate payment posting with remittance codes is the foundation for this analysis.
Biosimilars and payer preferences
Biosimilars have become a major factor in oncology drug payment. For Medicare Part B, biosimilars are paid based on their own average sales price plus an add-on calculated from the reference product, which can make biosimilars financially attractive for practices. Commercial plans and Medicare Advantage plans increasingly name preferred biosimilars and require them before approving a reference biologic or a nonpreferred biosimilar. Because preferences differ by plan and change over time, a practice may need to stock several versions of the same molecule. Keep a matrix of each major plan's preferred products, authorization requirements, and payment terms, and review it when plans publish formulary updates. Make sure the HCPCS code and modifiers billed match the specific product given, since biosimilars have their own codes. Billing the wrong product code is a frequent cause of denials and can also distort the practice's inventory reconciliation.
Frequently asked questions
How often does Medicare update drug payment rates?
CMS publishes Part B ASP payment limits quarterly.
Do commercial plans pay ASP-based rates?
Some do, as a percentage of ASP, while others use different benchmarks or fixed fee schedules. Check each contract.
What is white bagging?
A specialty pharmacy ships a patient-specific drug to the practice. The practice bills administration but not the drug.
Are JW and JZ modifiers required by commercial plans?
Medicare requires them for single-dose containers. Commercial plans may have their own rules, so verify each payer.
How can we find drug underpayments?
Compare paid amounts to expected payment by payer and date of service, and investigate variances by drug.
Sources and further reading
Need help with oncology billing? See our Oncology medical billing services.
Related articles
This article is general information, not legal or coding advice. Always check current CPT®, ICD-10-CM, CMS and payer guidance. Questions? Contact us.